

ASX Announcement

Medibio Limited – 6 April 2023



Update on Share Purchase Plan Timetable

Melbourne, Australia and Minneapolis, MN – 6 April 2023: Medibio Limited ("MEB," "Medibio" or "Company") (ASX: MEB) (OTCPINK: MDBIF) provides the following updates in regard to the share purchase plan announced to the market on 15 February 2023 (**SPP**) and as detailed in the SPP Prospectus lodged with ASX on 2 March 2023 (**Prospectus**).

The Company wishes to advise the following changes to the SPP timetable announced on 24 February 2023 and as detailed in the Prospectus lodged with ASX on 2 March 2023.

Update to Indicative Timetable for SPP

In order to settle under SPP the Company needs to obtain Shareholder approval for the issue of the shares and options. To this end, the Company has not had the time to issue the Notice of Meeting for the Extraordinary General Meeting and it is therefore required to extend the SPP timetable to accommodate for this. The Company expects to issue a Notice of Meeting to Shareholders in the coming weeks once ASX has finalised its review. Accordingly, the timetable for the SPP which was announced on 24 February 2023 and included in the Prospectus is updated as follows:

Event	Date*
SPP Offer Record Date	7.00pm (Sydney time), 14 February 2023
Announcement of Placement and SPP Offer	15 February 2023
Settlement of Placement	20 February 2023
Issue and trading of Shares under Placement	21 February 2023
Lodgement of Prospectus with ASIC and ASX	2 March 2023
SPP Offer Opening Date and Shortfall Opening Date	2 March 2023
Lodgement of EGM Notice with ASX	24 April 2023
EGM conducted	23 May 2023
SPP Offer Closing Date	5.00pm (Sydney time), 23 May 2023
Issue of SPP Shares and SPP Options under SPP Offer	30 May 2023
Trading of all Shares and Options (subject to ASX Listing Rules)	30 May 2023
SPP Shortfall Offer Closing Date	4 July 2023

ASX Announcement

Medibio Limited – 6 April 2023



**The above timetable is indicative only and subject to change. The quotation of New Shares is subject to ASX approval. Subject to the ASX Listing Rules and Corporations Act and other applicable laws, the Company reserves the right to vary these dates, without notice. Any extension of the SPP will have a consequential effect on the issue date of the securities.*

Supplementary Prospectus in respect of SPP

In light of the above mentioned update the Company intends to lodge a supplementary prospectus in respect of the SPP. The purpose of the supplementary prospectus will be to update investors in relation to the following matters:

- the updates in relation to the amended SPP timetable; and
- to enclose the investor presentation which will be provided to certain investors looking to participate in any shortfall under the SPP.

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Medibio Investor and Media Enquiries:

investors@medibio.com.au

+61 3 9692 7222